IntelGenx Files Non-Provisional U.S. Patent Application for Oil-Based Active Ingredients
April 16 2019 - 08:00AM
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading
oral drug delivery company, today announced that it has filed a new
non-provisional patent application at the Unites States Patent and
Trademark Office entitled “Lipophilic Active Oral Film Formulation
And Method Of Making The Same.”
The patent application covers a newly-developed
platform that enables the incorporation of oil-based (lipophilic)
active ingredients into oral film formulations. This new platform,
suitable for both VersaFilmTM and VetaFilmTM, is compatible with
several of IntelGenx’ current projects including Montelukast,
Loxapine and cannabis-infused films. The technology may also be
used when more than one active ingredients, such as THC and
CBD, are applied in a single film product.
“This new filing adds to the global intellectual
property estate that we are building for VersaFilmTM and
VetaFilmTM,” said Dr. Horst G. Zerbe, President and CEO of
IntelGenx. “We anticipate that this application will also be filed
in several other international jurisdictions as the application
progresses in the United States.”
About IntelGenx
Established in 2003, IntelGenx is a leading oral
drug delivery company primarily focused on the development and
manufacturing of innovative pharmaceutical oral films based on its
proprietary VersaFilmTM and VetaFilmTM technology platforms.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility, which was established for
oral film technology platforms, offers by supporting lab-scale to
pilot- and commercial-scale production. More information about the
company can be found at www.intelgenx.com.
Forward Looking Statements
This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQX has
neither approved nor disapproved the contents of this press
release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information please contact:
Stephen KilmerInvestor Relations (514) 331-7440 ext
232stephen@intelgenx.com
Or
Andre Godin, CPA, CAExecutive Vice-President and CFOIntelGenx
Corp.(514) 331-7440 ext 203andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Mar 2023 to Mar 2024